Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB4A | P04350 | 2/20 | 0.74 |
| ▸ | TUBB | P07437 | 2/20 | 0.74 |
| ▸ | TUBA3C | P0DPH7 | 2/20 | 0.74 |
| ▸ | TUBA1B | P68363 | 2/20 | 0.74 |
| ▸ | TUBA4A | P68366 | 2/20 | 0.74 |
| ▸ | TUBB4B | P68371 | 2/20 | 0.74 |
| ▸ | TUBB3 | Q13509 | 2/20 | 0.74 |
| ▸ | TUBB2A | Q13885 | 2/20 | 0.74 |
| ▸ | TUBB8 | Q3ZCM7 | 2/20 | 0.74 |
| ▸ | TUBA3E | Q6PEY2 | 2/20 | 0.74 |
| ▸ | TUBA1A | Q71U36 | 2/20 | 0.74 |
| ▸ | TUBA1C | Q9BQE3 | 2/20 | 0.74 |
| ▸ | TUBB6 | Q9BUF5 | 2/20 | 0.74 |
| ▸ | TUBB2B | Q9BVA1 | 2/20 | 0.74 |
| ▸ | TUBB1 | Q9H4B7 | 2/20 | 0.74 |
| ▸ | RAB9A | P51151 | 14/20 | 0.68 |
| ▸ | NPC1 | O15118 | 13/20 | 0.68 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12066528 | 1.00 | TUBB4A (0.74) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL1508832 | 0.85 | TUBB4A (1.00) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL1508835 | 0.85 | TUBB4A (1.00) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL29539476 | 0.84 | ALDH1A1 (0.81) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL1086983 | 0.84 | ALDH1A1 (0.81) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL1086985 | 0.84 | ALDH1A1 (0.81) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL30725598 | 0.82 | TUBB4A (0.71) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL12351273 | 0.82 | RAB9A (1.00) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL3533833 | 0.80 | RAB9A (1.00) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL3533832 | 0.80 | RAB9A (1.00) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3318561-B1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC (US) | 2021-12-22 | — | — | EP | disclosed |
| US-10562916-B2 | Substituted quinoxalines as PDE-10 inhibitors | SUNOVION PHARMACEUTICALS, INC. (US) | 2020-02-18 | — | — | US | disclosed |
| EP-2576540-B1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC (US) | 2019-09-04 | — | — | EP | disclosed |
| EP-3318561-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | Sunovion Pharmaceuticals Inc. (US) | 2018-05-09 | — | — | EP | disclosed |
| US-20180037590-A1 | SUBSTITUTED QUINOLINES AS PDE-10 INHIBITORS | SUNOVION PHARMACEUTICALS INC. | 2018-02-08 | — | — | US | disclosed |
| US-9834564-B2 | Substituted quinolines as PDE-10 inhibitors | SUNOVION PHARMACEUTICALS INC. (US) | 2017-12-05 | — | — | US | disclosed |
| US-20150166571-A1 | Heteroaryl Compounds and Methods of Use Thereof | SUNOVION PHARMACEUTICALS INC. | 2015-06-18 | — | — | US | disclosed |
| US-8969349-B2 | Substituted quinoxalines and quinoxalinones as PDE-10 inhibitors | SUNOVION PHARMACEUTICALS INC. (US) | 2015-03-03 | — | — | US | disclosed |
| US-20130158003-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC (US) | 2013-06-20 | — | — | US | disclosed |
| WO-2011150156-A2 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2011-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180037590-A1 | SUBSTITUTED QUINOLINES AS PDE-10 INHIBITORS | PDE10A, PDE2A, PDE3A | TUBB4A 2928/4885TUBB 3097/4885TUBA3C 2608/4885 |
| US-20130158003-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | COMT, GPR119, NLN | TUBB4A 3053/4885TUBB 3336/4885TUBA3C 1385/4885 |
| US-10562916-B2 | Substituted quinoxalines as PDE-10 inhibitors | PDE4A, PDE2A, PDE9A | TUBB4A 2968/4885TUBB 2793/4885TUBA3C 3888/4885 |
| US-20150166571-A1 | Heteroaryl Compounds and Methods of Use Thereof | COMT, GPR119, NLN | TUBB4A 3053/4885TUBB 3336/4885TUBA3C 1385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.